View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 28, 2021

Kezar doses first subject in Phase I trial of solid tumour treatment

The open-label, multicentre Phase I trial will evaluate KZR-261 in patients with solid tumour malignancies.

Kezar Life Sciences has announced the dosing of the first subject in the Phase I KZR-261-101 clinical trial of a new therapy, KZR-261, in advanced solid tumour malignancies.

Discovered by Kezar, the broad-spectrum anti-tumour agent KZR-261 acts through direct interaction and hinders Sec61 activity.

The open-label, multicentre Phase I trial in subjects with solid tumour malignancies will be carried out in two parts, dose-escalation and dose-expansion.

It will assess the tolerability, safety, pharmacokinetics and pharmacodynamics of KZR-261 in patients with locally advanced or metastatic disease.

The trial will also evaluate the initial anti-tumour activity of the treatment.

On concluding safety analysis of all dose-escalation arms and deciding on the maximum tolerated dose or administered dose, the therapy will be assessed for safety and preliminary efficacy.

This will be carried out in four tumour-specific arms and one all-tumour arm for determining doses recommended for Phase II clinical trials.

Kezar Life Sciences co-founder and CEO John Fowler said: “Dosing the first patient with KZR-261, the first clinical candidate from our novel protein secretion platform, is an exciting milestone for Kezar as we continue to advance our oncology program and mature into a multi-asset therapeutics company.

“We believe KZR-261 has a differentiated therapeutic profile, which could translate into broad potential across the oncology landscape.”

KZR-261 has shown various promising features that lead to its potential to be an anti-cancer agent.

A Phase I trial is currently progressing to treat solid tumour malignancies.

Kezar Life Sciences’ lead development candidate KZR-616 is a selective immunoproteasome inhibitor and is being assessed in Phase II studies for lupus nephritis, dermatomyositis and polymyositis treatments.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy